ROE

A top financial forum is urging a GST hike, corporate tax cuts, and a radical revamp of retirement savings in its bold 2026 federal budget proposal.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With booming revenue and a new premium product on the horizon, Grindr's CFO is set to outline the company's ambitious future to investors this month.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

After unprecedented growth, Clear Fork Bank names a new CEO known for community ties, signaling a strategy to blend legacy values with future expansion.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

Dubai-based robotics firm Micropolis AI is under scrutiny after a delayed annual report triggered a warning from the NYSE American exchange.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Despite a historic tariff shock, new data shows middle market dealmaking adapted and thrived, with private equity rewriting its playbook for a new era.

As it turns six, crypto platform BYDFi expands into traditional finance, bolsters global regulatory compliance, and launches a $1M anniversary event.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

The South Korean tobacco giant hits record revenue as its international strategy pays off, while it diversifies into nicotine pouches for future growth.